Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.
Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.
Faeth Therapeutics reported third quarter 2026 financial results, ending the period with $174.8 million in cash and marketable securities. The company highlighted the receipt of FDA Fast Track designation for its lead program PIKTOR in endometrial cancer and expects topline Phase 2 data by year-end 2026.
Term
Q3 2026
“We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option. We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027.”
Faeth Therapeutics reported a significant net loss of $206.6 million for the nine months ended September 30, 2026, primarily driven by a $133.0 million charge for acquired in-process research and development. The company significantly strengthened its balance sheet during the period, ending with $174.8 million in cash and marketable securities following a private placement and acquisition.
Faeth Therapeutics increased its board size from six to seven and appointed Adam Schayowitz, Ph.D., as a Class III director. Dr. Schayowitz, currently EVP and Head of R&D at Zymeworks, brings extensive oncology drug development experience from previous roles at Pfizer and Tesaro. He will receive a standard non-employee director compensation package, including an initial option to purchase 25,000 shares of common stock.
Faeth Therapeutics increased its board size from five to six and appointed co-founder Karen Vousden, Ph.D., as a Class II director and member of the Compensation Committee. Dr. Vousden, a renowned cancer biologist and current director at Bristol Myers Squibb, will receive a standard non-employee director compensation package including an option to purchase 25,000 shares of common stock.